Collectively, our results uncover a novel ARF6‐PI3K/AKT/mTOR signaling axis that drives AML progression, suggesting that targeting this pathway may represent a promising therapeutic strategy for this challenging malignancy. The gene discussed is ARF6; the disease is acute myeloid leukemia.